BC Gov News. (2022, May 31).
BC receives exemption to decriminalize possession of some illegal drugs for personal use. Mental Health and Addictions. -
https://news.gov.bc.ca/releases/2022MMHA0029-000850
Hawk, M., Coulter, R. W. S., Egan, J. E., Fisk, S., Reuel Friedman, M., Tula, M., & Kinsky, S. (2017). Harm reduction principles for healthcare settings. Harm Reduction Journal, 14(1), 70.
https://doi.org/10.1186/s12954-017-0196-4
Levengood, T. W., Yoon, G. H., Davoust, M. J., Ogden, S. N., Marshall, B. D. L., Cahill, S. R., & Bazzi, A. R. (2021). Supervised Injection Facilities as Harm Reduction: A Systematic Review. American Journal of Preventive Medicine, 61(5), 738–749.
https://doi.org/10.1016/j.amepre.2021.04.017
Ng, J., Sutherland, C., & Kolber, M. R. (2017). Does evidence support supervised injection sites? Canadian Family Physician Medecin de Famille Canadien, 63(11), 866.Pergolizzi, J. v., Dahan, A., Ann LeQuang, J., & Raffa, R. B. (2021). Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. Journal of Clinical Pharmacy and Therapeutics, 46(6), 1501–1504.
https://doi.org/10.1111/jcpt.13462
Plunkett, A. R., & Peden, R. M. (2019). Opioid maintenance, weaning and detoxification techniques; where we have been, where we are now and what the future holds: an update. Pain Management, 9(3), 297–306.
https://doi.org/10.2217/pmt-2018-0046
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 3(2), e1920622.
https://doi.org/10.1001/jamanetworkopen.2019.20622
Xie, E., Green, S., Puri, N., & Sheikh, H. (2017). Updating our language around substance use disorders. Canadian Medical Association Journal, 189(50), E1566–E1566.
https://doi.org/10.1503/cmaj.733490
Centres for Disease Control and Prevention. (2018
https://www.cdc.gov/niosh/topics/opioids/response.html
CBC- 2021
https://www.cbc.ca/news/canada/calgary/federal-election-opioid-drugs-crisis-1.6171434
Map for Naloxone Kit Dist
https://public.tableau.com/app/profile/surveillance.reporting.ahs/viz/MapforNaloxoneKitDistribution/NaloxoneDistributionMapAdditional Relevant Articles:
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., Hart, C., Kerr, T., Lajous, A. M., Lewis, S., Martin, N., Mejía, D., Camacho, A., Mathieson, D., Obot, I., … Beyrer, C. (2016). Public health and international drug policy.
The Lancet,
387(10026), 1427–1480.
https://doi.org/10.1016/S0140-6736(16)00619-X
Daniels, C., Aluso, A., Burke-Shyne, N., Koram, K., Rajagopalan, S., Robinson, I., Shelly, S., Shirley-Beavan, S., & Tandon, T. (2021). Decolonizing drug policy.
Harm Reduction Journal,
18(1), 120.
https://doi.org/10.1186/s12954-021-00564-7
Dea, S. (2020). Toward a Philosophy of Harm Reduction.
Health Care Analysis,
28(4), 302–313.
https://doi.org/10.1007/s10728-020-00405-x
Huhn, A. S., & Gipson, C. D. (2021). Promoting harm reduction as a treatment outcome in substance use disorders.
Experimental and Clinical Psychopharmacology,
29(3), 217–218.
https://doi.org/10.1037/pha0000494
Pauly, B. (2008). Harm reduction through a social justice lens.
International Journal of Drug Policy,
19(1), 4–10.
https://doi.org/10.1016/j.drugpo.2007.11.005
Shearer, D., Fleming, T., Fowler, A., Boyd, J., & McNeil, R. (2019). Naloxone distribution, trauma, and supporting community-based overdose responders.
International Journal of Drug Policy,
74, 255–256.
https://doi.org/10.1016/j.drugpo.2018.11.008
Vicknasingam, B., Narayanan, S., Singh, D., & Chawarski, M. (2018). Decriminalization of drug use.
Current Opinion in Psychiatry,
31(4), 300–305.
https://doi.org/10.1097/YCO.0000000000000429